Michael J. Fox Foundation Announces $2 Million Funding Commitment to Drive Development of Parkinson's Disease Biomarker Pipeline
“Lack of biomarkers is a major impediment to the development of disease-modifying treatments for Parkinson’s disease, in large part because outcomes of clinical trials are extremely difficult to measure,” said Katie Hood, CEO. “While considered a high-risk pursuit by many, The Michael J. Fox Foundation will continue to push biomarker research because development of PD biomarkers would be a major tipping point for the field, greatly accelerating the development of transformative new therapies.”
The Foundation has been a field leader in the development of PD biomarkers for several years. Approximately $9 million in MJFF investment to date has resulted in the emergence of several lead biomarker candidates. Today’s additional $2 million, directed toward biomarker discovery, underscores that commitment. Biomarkers 2009 will prioritize continued development of two separate types of biomarkers, both of major importance to PD therapeutics development: disease biomarkers and drug biomarkers.
Disease biomarkers are distinctive biological features or changes that are consistently different in people with PD than in people without PD. Identifying one or more disease biomarkers would allow researchers to diagnose earlier, track disease progression and identify appropriate subjects for clinical trials. Drug biomarkers are critical for objectively assessing whether a given drug is reaching brain areas of interest and/or achieving a desired effect.
Abbreviated information for applicants is below. Full details are available at www.michaeljfox.org/research.cfm.
Total available funding: $2 million
Deadline: 6 p.m. ET, Tuesday, June 23, 2009
Funding Anticipated: November/December 2009